This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Pacific Biosciences (PACB) Loses 4.1% Post Reporting Q3 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter.
Avanos Medical (AVNS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continued to gain from core Chronic Care segment in the third quarter.
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.
Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.
Chemed's (CHE) Shares Up on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Chemed (CHE) reports solid revenue growth across key subsidiaries in third-quarter results.
Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates
by Zacks Equity Research
Accuray (ARAY) registered growth in Service revenues in Q1.
STERIS' (STE) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.
Syneos Health (SYNH) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed's (RMD) overall increase in Q1 revenues is driven by robust performance of its mask and device product portfolios on increased demand for ventilators and ventilator masks.
Exact Sciences (EXAS) Loses 5.6% Despite Beating Q3 Earnings
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q3 earnings.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.
OPKO Health (OPK) Loses 16.2% Despite In-Line Q3 Earnings
by Zacks Equity Research
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
Allscripts (MDRX) Declines 1.9% Despite Q3 Earnings Beat
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during the third quarter.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.
Integer Holdings (ITGR) Q3 Earnings Beat Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect weak segmental performance.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Stryker (SYK) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong segmental performance.
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Merit Medical (MMSI) Rallies 4.8% Post Q3 Earnings Beat
by Zacks Equity Research
Merit Medical (MMSI) reported growth in revenues at Cardiovascular segment in the third quarter.
DaVita (DVA) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
DaVita (DVA) saw strength in dialysis services in the United States in the third quarter.
The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Thermo Fisher, SAP, BMY, NextEra and Morgan Stanley